Monthly Archives: September, 2019

Rep. Loebsack of Iowa Co-Sponsors Functional Gastrointestinal and Motility Disorders Research Enhancement Act (HR 3396)

According to IFFGD and the official Congressional legislative database Congress.gov, in the last week, Representative Dave Loebsack (D-IA-2)  has added his support as a co-sponsor for HR 3396, the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2019. This is the third time in different Congresses that he has supported versions of the Act, …

Continue reading

Functional Gastrointestinal and Motility Disorders Research Enhancement Act (HR 3396) Gains Bipartisan Support of 4 New Co-Sponsors From 4 New States

According to IFFGD and the official Congressional legislative database Congress.gov, so far in September 2019, four members of the U.S House of Representatives have added their support as co-sponsors for HR 3396, the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2019. They represent both political parties and four different states new to the …

Continue reading

U.S. FDA Approves Tenapanor (Ibsrela) for Adults with IBS with Constipation (IBS-C)

This past week, the U.S Food and Drug Administration (FDA) approved the sale and distribution of a new medication for irritable bowel syndrome with constipation (IBS-C), tenapanor, to be known by the brand name Ibsrela. Tenapanor, a 50 mg. daily oral medication is approved for adults. It has not been approved for youth under the …

Continue reading

Phone Research: iSTEP Study for Mothers with Irritable Bowel Syndrome (IBS), Seattle Children’s Research Institute, September 2019

The following telephone research study seeking volunteers is being conducted by the Seattle Children’s Research Institute in Seattle, Washington, USA. It is open to women with a diagnosis of IBS and abdominal pain who are also parenting a child or children ages 5-10 who do not have abdominal pain. The study consists of  a 30 …

Continue reading